Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Salmeterol is a potent and selective β2-adrenoceptor agonist (EC50 = 5.3 nM); bronchodilator. Unlike other β2 agonists, binds to exo-site domain of β2 receptors, producing a slow onset of action and prolonged activation.
ln Vivo |
Combined treatment with salmeterol (0.16 mg/kg) and formoterol (0.32 mg/kg) had a beneficial impact on rats with chronic obstructive pulmonary disease (COPD) [3].
|
---|---|
Cell Assay |
Cell proliferation assay [2]
Cell Types: Human T lymphocytes (THP-1 cells) Tested Concentrations: 0.001, 0.01, 0.05, 0.2, 1, 5, and salmeterol (0.001-25 μM) inhibit human T floating [2] . 25 µM Incubation Duration: Experimental Results: Th2 cell proliferation was inhibited in a concentration-dependent manner. |
Animal Protocol |
Animal/Disease Models: Male C57BL/6 mice (6-8 weeks old, body weight: 32-35 g) [3]
Doses: salmeterol (0.16 mg/kg) and/or formoterol (0.32 mg/kg) Route of Administration: The efficacy of combination therapy was studied in this model for 56 days. The observation period is long. Experimental Results: COPD mice had Dramatically improved COPD assessment test scores. |
References |
[1]. Panayiotis A Procopiou, et al. The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group. Bioorg Med Chem. 2011 Oct 15;19(20):6026-32.
[2]. Malcolm Johnson. Effects of beta2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol. 2002 Dec;110(6 Suppl):S282-90. [3]. Zhiyuan Wang, et al. Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease. Exp Ther Med. 2018 Feb;15(2):1538-1545. |
Molecular Formula |
C25H37NO4
|
---|---|
Molecular Weight |
415.5656
|
CAS # |
89365-50-4
|
Related CAS # |
Salmeterol xinafoate;94749-08-3
|
SMILES |
O(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C([H])([H])C([H])(C1C([H])=C([H])C(=C(C([H])([H])O[H])C=1[H])O[H])O[H]
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~240.63 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.02 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.02 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.02 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4063 mL | 12.0317 mL | 24.0633 mL | |
5 mM | 0.4813 mL | 2.4063 mL | 4.8127 mL | |
10 mM | 0.2406 mL | 1.2032 mL | 2.4063 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.